PTC Therapeutics, Inc.

NasdaqGS:PTCT Stock Report

Market Cap: US$3.5b

PTC Therapeutics Valuation

Is PTCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PTCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PTCT ($46.24) is trading below our estimate of fair value ($124.4)

Significantly Below Fair Value: PTCT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PTCT?

Key metric: As PTCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PTCT. This is calculated by dividing PTCT's market cap by their current revenue.
What is PTCT's PS Ratio?
PS Ratio4x
SalesUS$900.66m
Market CapUS$3.49b

Price to Sales Ratio vs Peers

How does PTCT's PS Ratio compare to its peers?

The above table shows the PS ratio for PTCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
VCYT Veracyte
7.5x9.1%US$3.0b
ACAD ACADIA Pharmaceuticals
3x9.4%US$2.8b
RARE Ultragenyx Pharmaceutical
7.8x31.6%US$4.0b
FOLD Amicus Therapeutics
5.9x19.5%US$2.9b
PTCT PTC Therapeutics
4x6.1%US$3.5b

Price-To-Sales vs Peers: PTCT is good value based on its Price-To-Sales Ratio (4x) compared to the peer average (6.1x).

Price to Sales Ratio vs Industry

How does PTCT's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.7x20.8%
PTCT PTC Therapeutics
 4x6.1%US$3.49b
BIIB Biogen
2.2x1.3%US$21.48b
MRNA Moderna
3x5.8%US$15.22b
PTCT 4.0xIndustry Avg. 9.7xNo. of Companies134PS01632486480+
134 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.7x27.5%
PTCT PTC Therapeutics
 4x63.1%US$3.49b
No more companies

Price-To-Sales vs Industry: PTCT is good value based on its Price-To-Sales Ratio (4x) compared to the US Biotechs industry average (9.4x).

Price to Sales Ratio vs Fair Ratio

What is PTCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PTCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4x
Fair PS Ratio3.4x

Price-To-Sales vs Fair Ratio: PTCT is expensive based on its Price-To-Sales Ratio (4x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PTCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$46.24
US$58.71
+27.0%
23.7%US$80.00US$32.00n/a14
Dec ’25US$43.88
US$46.14
+5.2%
27.3%US$68.00US$26.00n/a14
Nov ’25US$40.47
US$41.50
+2.5%
26.3%US$64.00US$26.00n/a14
Oct ’25US$36.05
US$39.71
+10.2%
27.7%US$64.00US$26.00n/a14
Sep ’25US$35.32
US$39.38
+11.5%
28.8%US$64.00US$26.00n/a13
Aug ’25US$32.69
US$38.33
+17.3%
30.8%US$62.00US$25.00n/a12
Jul ’25US$31.17
US$38.75
+24.3%
30.3%US$62.00US$25.00n/a12
Jun ’25US$36.36
US$36.73
+1.0%
28.2%US$53.00US$25.00n/a11
May ’25US$34.16
US$29.50
-13.6%
30.6%US$45.00US$16.00n/a12
Apr ’25US$28.59
US$29.08
+1.7%
31.9%US$45.00US$15.00n/a12
Mar ’25US$31.95
US$28.17
-11.8%
34.0%US$45.00US$15.00n/a12
Feb ’25US$26.03
US$27.77
+6.7%
34.9%US$45.00US$15.00n/a13
Jan ’25US$27.56
US$28.62
+3.8%
35.4%US$51.00US$17.00n/a13
Dec ’24US$23.99
US$28.08
+17.1%
35.9%US$51.00US$17.00US$43.8812
Nov ’24US$18.45
US$28.08
+52.2%
35.9%US$51.00US$17.00US$40.4712
Oct ’24US$22.41
US$37.42
+67.0%
40.8%US$73.00US$22.00US$36.0512
Sep ’24US$40.08
US$52.13
+30.1%
21.2%US$73.00US$35.00US$35.3215
Aug ’24US$40.67
US$53.47
+31.5%
22.0%US$73.00US$35.00US$32.6915
Jul ’24US$40.67
US$54.07
+32.9%
21.1%US$73.00US$35.00US$31.1715
Jun ’24US$43.50
US$54.20
+24.6%
21.5%US$75.00US$35.00US$36.3615
May ’24US$55.17
US$52.60
-4.7%
19.5%US$71.00US$35.00US$34.1615
Apr ’24US$48.44
US$51.53
+6.4%
19.3%US$75.00US$35.00US$28.5915
Mar ’24US$45.24
US$51.14
+13.0%
17.6%US$66.00US$35.00US$31.9514
Feb ’24US$47.37
US$50.36
+6.3%
20.9%US$68.00US$35.00US$26.0314
Jan ’24US$38.17
US$50.29
+31.7%
21.2%US$69.00US$35.00US$27.5614
Dec ’23US$41.55
US$51.46
+23.9%
19.8%US$69.00US$36.00US$23.9913

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 05:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PTC Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Huidong WangBarclays
Geoffrey MeachamBarclays